NUVISAN’s Discovery Pharmacology experts also support projects to identify and/or deconvolute disease-relevant targets across a variety of therapeutic areas. Using our state-of-the-art functional genomics and cellular assay platforms we offer both in vitro and in vivo
Our in vitro, ex vivo, and in vivo models are complemented by the analysis of human samples. This assay portfolio enables us to perform thorough mode-of-action studies to optimize your compounds. We also utilize these assays to facilitate identification and validation of pharmacodynamic and predictive biomarkers. With our advanced in silico analysis tools, together with a diverse panel of disease-relevant in vitro and in vivo models, our cross-indication research team supports the indication expansion and repurposing of your existing assets.
Thus, we assist you to
- get an innovative and substantiated start for your drug development program
- enable early de-risking of your drug discovery project thorough target validation
- find and optimize a lead by delivering high-quality data to explore structure–activity relationships
- evaluate and preclinically validate target engagement/pharmacodynamic and predictive biomarkers
- identify the most suitable proof-of-concept indication for your asset
The following links provide further information:
With decades of industry experience, our interdisciplinary teams have the knowledge, skills, and equipment to drive your project to the next level.
